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Abstract: There is a large and growing body of literature focusing on the use of oral magnesium
(Mg) supplementation for improving glucose metabolism in people with or at risk of diabetes. We
therefore aimed to investigate the effect of oral Mg supplementation on glucose and insulin-sensitivity
parameters in participants with diabetes or at high risk of diabetes, compared with a placebo. Several
databases were searched investigating the effect of oral Mg supplementation vs placebo in patients
with diabetes or conditions at high risk of diabetes. Data were reported as standardized mean
differences (SMDs) with their 95% confidence intervals (CIs) using follow-up data of glucose and
insulin-sensitivity parameters. Compared with placebo, Mg supplementation reduced fasting plasma
glucose in people with diabetes. In people at high risk of diabetes, Mg supplementation significantly
improved plasma glucose per se, and after a 2 h oral glucose tolerance test. Furthermore, Mg
supplementation demonstrated an improvement in insulin sensitivity markers. In conclusion, Mg
supplementation appears to have a beneficial role and improves glucose parameters in people with
diabetes. Moreover, our work indicates that Mg supplementation may improve insulin-sensitivity
parameters in those at high risk of diabetes.
Keywords: magnesium; diabetes; glucose; meta-analysis
1. Introduction
The literature regarding the health benefits of magnesium (Mg) is exponentially in-
creasing [1]. Recent literature has reported that Mg, involved in more than 300 enzymatic
reactions [2], has a wide spectrum of action in cardiovascular [3,4], pregnancy [5], gastroin-
testinal [6], in infectious [7] and metabolic diseases [8], such as diabetes.
In a previous systematic review and meta-analysis, it was reported that Mg supplemen-
tation, compared to placebo, improves several glucose and insulin-sensitivity parameters in
people affected by diabetes or have conditions (such as obesity) that put them at increased
risk of developing diabetes [9]. In a large meta-analysis including more than 500,000 partic-
ipants it was found that higher Mg intake is associated with a significant decrease in the
incidence of diabetes [10], supported by evidence with a low risk of bias [1]. Unfortunately,
the proportion of people meeting the recommended daily allowance (RDA) for Mg is still
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low. Therefore, in some high risk populations (such as diabetes, older people and pregnant
women), oral supplementation is often necessary [11].
Regarding diabetes, several randomized, double-blind controlled trials (RCTs) have
investigated the effect of oral Mg supplementation on glucose metabolism parameters.
However, these RCTs have an important limitation since they only include a small number
of participants [9], as highlighted in a previous systematic review and meta-analysis
regarding this topic [12].
Given this background, we conducted a systematic review of RCTs investigating the
effect of oral Mg supplementation on glucose and insulin-sensitivity parameters in partici-
pants with diabetes or at high risk of diabetes compared with a placebo. It is hypothesized
that Mg supplementation would improve glucose and insulin outcomes in those with
diabetes and in those with conditions that put them at a high risk of developing diabetes.
2. Materials and Methods
This systematic review adhered to the PRISMA statement [13] and followed a pre-
planned, but unpublished protocol that can be requested by contacting the correspond-
ing author.
2.1. Data Sources and Searches
Two investigators (NV and DP) independently conducted a literature search using
several databases including PubMed, EMBASE, SCOPUS, Cochrane Central Register of
Controlled Trials and Clinicaltrials.gov without language restriction, from 31 January 2016
until 26 October 2021, including RCTs investigating the effect of oral Mg vs. placebo in
patients with diabetes or at high risk of developing diabetes. In a previous meta-analysis
of the present group literature on this topic was screened up to 31 January 2016.
In PubMed, the following search strategy was used: (magnesium) AND (‘diabet*’ OR
‘glucose’ OR glycosylated hemoglobin OR ‘insulin’) AND (‘clinical trial’ OR ‘randomized
controlled trial’ OR ‘placebo’), adapting the search according to the database. Conference
abstracts and reference lists of included articles were hand searched to identify any potential
additional relevant articles. Any inconsistencies were resolved by consensus, with a senior
author participating in the first meta-analysis on this topic [9].
2.2. Study Selection
Inclusion criteria for this meta-analysis were: (i) being an RCT; (ii) double-blind design;
(iii) participants with diabetes or subjects at high risk of developing diabetes included;
(iv) use of oral magnesium supplementation; (v) assessment of glucose metabolism or
insulin sensitivity parameters (see below for further details); (vi) sufficient quality, as
assessed by Jadad’s scale [14] ≥ 3/5 points. We considered it diabetes when the diagno-
sis was made according to the criteria proposed by the American Diabetes Association,
i.e.,: fasting plasma glucose (FPG) ≥ 126 mg/dl (=7.0 mmol/L), or 2 h PG ≥ 200 mg/dL
(=11.1 mmol/L) during oral glucose tolerance test (OGTT) with 75 g of glucose, or gly-
cosylated hemoglobin (HbA1C ≥ 6.5% (=48 mmol/mol), or random PG ≥ 200 mg/dL
(=11.1 mmol/L). [15] Several conditions were considered as placing people at high risk of
diabetes, including obesity/overweight, metabolic syndrome, renal failure, family history
of diabetes, prediabetes, and others. In the case of disagreement between the two reviewers,
a third senior reviewer with expertise in diabetes and metabolic disease (LD) was involved
and a consensus among the three reviewers was reached. RCTs were excluded if they: (i)
did not include humans; (ii) used a control group taking other substances than placebo; (iii)
investigated the effect of Mg supplementation on glucose/insulin-sensitivity parameters
in healthy participants.
2.3. Data Extraction
Two independent investigators (JD and DP) extracted key data from the included
articles in a standardized Excel spread sheet and a third independent investigator (NV)
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checked these data. For each article, we extracted data on authors, year of publication, coun-
try, glucose metabolism/insulin-sensitivity end points, condition, study design (crossover
or parallel), medications used for the treatment of diabetes, type of Mg used in the trial
with daily dosage, and follow-up duration (in weeks). Moreover, we extracted data on
treatment with Mg or placebo, mean age, body mass index (BMI), and number of women
at baseline. When information was missing, first and/or corresponding authors of the
original article were contacted at least four times to obtain unpublished data.
2.4. Outcomes
The primary outcomes were parameters of glucose metabolism and insulin sensitivity.
Regarding glucose metabolism, we included FPG, glycosylated hemoglobin (HbA1c),
plasma glucose after the 2 h OGTT. Regarding insulin sensitivity, we extracted data on
fasting insulin levels or after 2 h OGTT, homeostatic model assessment-insulin resistance
(HOMA-IR).
2.5. Quality Assessment
Two authors (JD and DP) completed scoring using the Jadad’s scale [14] for assessing
the quality of the RCTs included. This quantifies the trial quality based on the description
and appropriateness of randomization (2 points), blinding procedures (2 points) and
description of withdrawals (1 point). A value of 3 (over a maximum of 5) usually indicates
a low-quality study at high risk of bias [16].
2.6. Data Synthesis and Analysis
All analyses were performed using STATA version 14.0 (StataCorp). Outcomes with
at least two studies were meta-analyzed; outcomes with less than two studies, i.e., not
suitable to be included in meta-analyses were excluded.
The primary analysis compared parameters of glucose metabolism or insulin sensitiv-
ity between participants treated with oral Mg supplementation vs placebo. We calculated
the difference between the means of the treatment and placebo groups using follow-up data
through standardized mean differences (SMD) with their 95% confidence intervals (CIs),
applying a random-effect model [17]. Heterogeneity across studies was assessed by the I2
metric and χ2 statistics. In case of significant heterogeneity (I2 ≥ 50%, p < 0.05) and for out-
comes having at least four studies, we conducted a series of meta-regression analyses using
as moderators the continent in which the study was performed (categorized as America
vs. others), follow-up length, differences in baseline mean age, BMI and mean outcome
investigated between Mg and the placebo group [18]. For analyses regarding conditions
that included people at high risk of diabetes, the condition investigated (categorized as
overweight vs. others) was also explored as a possible mediator of heterogeneity.
As most of the studies reported data on plasma/serum Mg, this parameter was
considered when running meta-regression analysis to examine if differences in values of
Mg at follow-up between treated and placebo groups could affect the glucose metabolism
or insulin-sensitivity parameters at follow-up, independently from heterogeneity.
Publication bias was assessed by visually inspecting funnel plots and using the Begg–
Mazumdar Kendall tau [19] and the Egger bias test [18]. Then, to account for publication
bias, the trim-and-fill method was employed, based on the assumption that the effect sizes
of all the studies are normally distributed around the center of a funnel plot; in the event
of asymmetries, adjustment for the potential effect of unpublished (trimmed) studies is
employed [20].
For all analyses, a p-value less than 0.05 was considered statistically significant.
3. Results
3.1. Search Results
As shown in Figure 1, among 1606 records initially screened, 48 were retrieved as
full texts. Compared to the previous meta-analysis regarding this topic, nine new RCTs
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were available (three in people with diabetes and six at high risk of diabetes), but one
RCT, published in 2019 in diabetic patients, was retracted [21]. Moreover, another study
published in 2015 in gestational diabetes was retracted [22], leaving 25 RCTs eligible for
the present systematic review and meta-analysis [23–47].
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Figure 1. P IS flow-chart.
3.2. Study and Patient Characteristics
Full details regarding descriptive findings are reported in Supplementary Table S1
(for people with diabetes) and Supplementary Table S2 (high risk of diabetes).
Among the 13 studies including people with diabetes [23,26,31,34–43], the majority
(n = 11) focused on type 2 diabetes, one among pregnant women, one was made among
type 1 diabetic people. Ten RCTs had a parallel design, whilst three used a crossover design.
The 13 studies followed-up 361 diabetic participants treated with Mg compared to 359 with
placebo for a median of 12 weeks (range: 4–48). The participants treated with Mg were on
average 50.6 (vs 49.9 in placebo) years, had a mean BMI suggestive of overweight status
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and were predominantly women. Full details regarding the type of Mg supplementation
are reported in Supplementary Table S1, with Mg oxide being the most used. The quality of
the studies was generally high, as indicated by the Jadad’s scale (Supplementary Table S1).
Twelve RCTs [24,25,27–30,32,33,44–47] investigated the effect of Mg in conditions that
put people at high risk of developing diabetes. Five RCTs included participants being
overweight, two among people with metabolic syndrome, two prediabetes (defined as
the presence of FPG between 100 and 126 mg/dL or plasma glucose after OGTT between
140 and 200 mg/dL), two in women having polycystic metabolic syndrome, and one
metabolically obese with normal weight subjects, fully reported in Supplementary Table S2.
Eleven RCTs employed a parallel and only one a crossover design.
Altogether these studies followed up 477 participants treated with Mg and 480 with
placebo for a median of 14 (range: 4–24) weeks. The participants treated with Mg had
a mean age of 42.5 years, a mean BMI of 28.8 kg/m2 and were predominantly males;
the participants treated with placebo had a mean age of 45.6 years with a mean BMI of
28.9 kg/m2. Among the formulations available, similarly to the RCTs included diabetic
patients, Mg oxide was the most used form (Supplementary Table S2).
3.3. Meta-Analysis of the Effect of Magnesium on Glucose and Insulin-Sensitivity Parameters
3.3.1. People with Diabetes
As shown in Table 1, treatment with Mg significantly reduced FPG at follow-up
in 325 participants with diabetes compared to 331 taking placebo (n = 11 studies; SMD
= −0.426; 95%CI: −0.782 to −0.07; p = 0.02), this finding was characterized by a high
heterogeneity (I2 = 79.0%) (Supplementary Figure S1). Regarding HbA1c levels, Mg supple-
mentation did not improve this parameter in 301 participants compared to 307 participants
taking placebo (n = 10 studies; SMD = −0.134; 95%CI: −0.409 to 0.141; p = 0.34; I2 = 63.7%).
On the contrary, there was no evidence that Mg supplementation was able to improve
fasting insulin or HOMA-IR compared to placebo in four studies including 153 people
taking Mg and 149 taking placebo.











Mg Placebo SMD 95% CI p-Value
Egger’s Bias and
p-Value Trim and Fill (95%CI)
Classic Fail
Safe N
FPG 11 325 331 −0.426 −0.782; −0.07 0.02 79.0% −5.84; p = 0.02 Unchanged 65
HbA1c 10 301 307 −0.134 −0.409; 0.141 0.34 63.7% 5.02; p = 0.06 −0.25(−0.52; 0.03) [2 L] 6
Insulin 4 153 149 0.596 −0.576; 1.767 0.32 96.0% −0.16; p = 0.99 Unchanged 4
HOMA-IR 4 153 149 −0.169 −0.656; 0.319 0.50 76.9% −3.98; p = 0.63 Unchanged 4
High risk of diabetes
FPG 12 482 485 −0.344 −0.655; −0.03 <0.0001 81.2% 1.18; p = 0.63 −0.565(−0.860; −0.271) [4 L] 71
2hOGTT 3 105 105 −0.35 −0.62; −0.07 0.01 0% 1.38; p = 0.15 −0.41(−0.64 to −0.18) [2 L] 2
HbA1c 2 70 74 −0.275 −1.032; 0.481 0.48 69.3% Only two studies
Insulin 9 296 296 −0.059 −0.234; 0.116 0.51 11.0% −2.17; p = 0.09 Unchanged 0
HOMA-IR 9 340 344 −0.234 −0.443; −0.025 0.028 43.2% −0.57; p = 0.77 Unchanged 15
Abbreviations: CI—confidence intervals; FPG—fasting plasma glucose; HbA1c—glycosilated hemoglobin; HOMA-IR—homeostatic model
assessment-insulin resistance; Mg—magnesium; PLC—placebo; SMD—standardized mean difference.
3.3.2. People at High Risk of Diabetes
Table 1 reports the data regarding the effect of Mg, compared to placebo on glucose and
insulin-sensitivity parameters. Overall, Mg supplementation significantly improved FPG
in 482 subjects at high risk of diabetes compared to 485 randomized to placebo (11 RCTs;
SMD = −0.344; 95%CI: −0.655 to −0.03; p < 0.0001; I2 = 81.2%) (Supplementary Figure S2).
After trimming 4 studies at the left of the mean, these results remained statistically signifi-
cant (SMD = −0.565; 95%CI: −0.860 to −0.271).
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Similarly, Mg significantly improved 2hOGTT in 3 studies involving 210 participants
(SMD = −0.35; 95%CI: −0.62 to −0.07; I2 = 0%). Finally, compared to placebo, Mg signifi-
cantly decreases HOMA-IR in 9 studies (340 Mg vs. 344 placebo) (SMD = −0.234; 95%CI:
−0.443 to −0.025; p = 0.028; I2 = 43.2%) (Supplementary Figure S3), whilst no effect was
observed on HbA1c or serum insulin levels (Table 1).
3.4. Meta-Regression Analysis
Figure 2 reports the meta-regression analysis in people at high risk of diabetes using
as the exposure the differences in serum Mg between the treated and placebo groups at the
follow-up evaluation and the parameters of glucose or insulin-sensitivity metabolism as
outcomes. No significant associations were found between differences in serum Mg and
differences in FPG in people affected by diabetes.
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As shown in Figure 2a, higher differences in serum Mg between the treated and
placebo groups at follow-up were associated with higher differences in FPG (beta = −3.50;
95% CI: −5.77 to −1.23; p = 0.008; R2 = 71.7%) and HOMA-IR (beta = −1.87; 95% CI: −3.69
to −0.13; p = 0.04; R2 = 100%) (Figure 2b) in participants at high risk of diabetes. On the
contrary, as in the previous meta-analysis [9] regarding Mg supplementation on glucose
and insulin sensitivity parameters, continent in which the study was performed, follow-up
duration, differences in mean age, BMI or in mean outcome parameter at baseline between
Mg and placebo treated moderated the present results.
3.5. Compliance and Adverse Effects
In trials reporting the number of allocated participants and those finishing the study,
we observed that 82% of the allocated participants with diabetes and treated with Mg
vs. 75% treated with placebo finished the study, without any difference between the
groups (p = 0.55). Among participants with higher risk of diabetes, this figure was similar
(p = 0.81).
No severe side effects (for example, death or onset of cardiovascular diseases) emerged
in Mg or placebo groups, also considering the newly included RCTs. The most common
side effects observed were of a gastrointestinal nature, particularly diarrhea.
4. Discussion
In this systematic review and meta-analysis, including 25 placebo-controlled RCTs
on diabetes and conditions at high risk of diabetes, Mg supplementation significantly
improved FPG levels in diabetic patients. However, the inclusion of new literature in the
present updated review on patients at high risk of diabetes allowed for the observation
that oral Mg supplementation not only significantly decreased plasma glucose after 2 h
OGTT, but also FPG and HOMA-IR. Finally, the present review also suggests that in both
people with and at high risk of diabetes, Mg supplementation is well tolerated and without
significant adverse effects.
Mg may improve glucose metabolism and insulin sensitivity via several pathways.
First, it is known from experimental models that chronic Mg deficiency is associated with
impaired post-receptorial function, consequently reducing glucose utilization in cells [48].
Furthermore, Mg may have an action in improving insulin secretion from pancreatic beta-
cells [49]. However, the present meta-analysis failed to show any significant effect of Mg
compared to placebo in increasing serum insulin levels, whilst the main action of Mg seems
to be attributable to a decrease in insulin resistance as shown by the improvements in
HOMA-IR, particularly in those at high risk of diabetes [50], indicating that it is likely that
Mg acts better when a deposit of insulin is present [9]. Moreover, findings regarding the
improvement in insulin sensitivity are confirmed by other experimental results indicating
that Mg is able to decrease oxidative stress [51] and inflammatory parameters [52], two
main contributors of insulin resistance [53].
In this regard, it was observed in a review summarizing the role and the effect
of Mg in women affected by polycystic ovary syndrome that an association between
adequate Mg status and improved insulin resistance is likely, but that oral supplementation
with Mg is unlikely to improve glucose and insulin resistance parameters in this specific
population [54]. These findings were substantially confirmed by the RCTs included in
our meta-analysis and investigating the effect of oral Mg supplementation on glucose
metabolism in PCOS.
Furthermore, it is known that Mg may have important effects on other parameters
closely related to glucose metabolism, such as body composition, general health, and sleep
quality. In particular, serum Mg levels can be associated with inflammatory parameters,
as cited before and as reported in a nice case control study involving women affected by
fibromyalgia [55]. Moreover, Mg is important in muscle metabolism and it is known that
muscle is involved in insulin resistance [56]. Therefore, this pleiotropic effect can help to
better explain our findings. Finally, Mg could be important in ameliorating dyslipidemia
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(particularly if given together with selenium) [57], body composition parameters related to
adiposity [58] and sleep quality [59] and all these factors (dyslipidemia, obesity and poor
sleep quality) can contribute to poor glycemic control.
As shown in a meta-regression analysis, another relevant finding from the present
work is that the differences in serum Mg at follow-up between the treatment and placebo
groups significantly correlated with improvements in glucose and insulin sensitivity mark-
ers people who are diabetic and in people at high risk of diabetes, confirming findings from
the previous systematic review on this topic [9]. Unfortunately, due to the limited studies
for other more sophisticated measurements of Mg (e.g., urinary excretion during 24 h), we
were not able to assess whether these markers correlate with glucose or insulin sensitivity
metabolism, indicating the necessity of future studies in this direction. An important point,
however, is that a consistent proportion of the heterogeneity found in the present results is
explained by the differences between the Mg serum-treated and placebo groups, indicating
that RCTs characterized by a higher compliance and able to increase serum levels can
improve glucose metabolism parameters.
The findings of the present meta-analysis should be interpreted within its limitations.
First, RCTs consisted of small samples, with a short follow-up period, indicating the
necessity of large RCTs with a long follow-up period. Second, dosage/types of Mg largely
varied across RCTs: these factors may contribute to the high heterogeneity (I2 ≥ 50%)
observed in almost all outcomes included. Another limitation is that the evidence is mainly
limited to type 2 diabetes. Future studies are needed to understand if Mg supplementation
has a role in other types of diabetes, such as type 1 diabetes about which only one RCT
is available.
5. Conclusions
The present systematic review with meta-analysis suggests a beneficial role of Mg
supplementation compared to placebo in improving glucose parameters in diabetic patients,
as well as glucose and insulin sensitivity markers in subjects at high risk of diabetes. Future
larger studies, with a longer follow-up, are needed to further confirm these results.
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of diabetes; (c) HOMA-IR in people at high risk of diabetes.
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